BACKGROUND A number of non-systematic reviews on the effects or mechanisms of probiotics on improving dyslipidemia, fatty liver, and obesity have been available but inconclusive to determine the independent effects of...BACKGROUND A number of non-systematic reviews on the effects or mechanisms of probiotics on improving dyslipidemia, fatty liver, and obesity have been available but inconclusive to determine the independent effects of probiotics on each of the three conditions. AIM To perform a systematic review and meta-analysis on potential benefits of probiotics among individuals with fatty liver or obesity or hyperlipidemia. METHODS A systematic literature search was performed using PubMed and Embase. Adult participants of any gender without major comorbidities who received probiotics were considered following these criteria:(1) Studies on a single genus of probiotics with or without prebiotics;(2) Studies specifying the probiotic dosage into colony-forming units (CFUs);and (3) Studies on food-based probiotics were excluded. The primary outcome measures for fatty liver, obesity, and dyslipidemia were fibrosis score (kPa), body mass index (BMI;kg/m2), and serum lipid profiles (mg/dL), respectively. The secondary outcome measures for fatty liver and obesity were liver enzymes (U/L) and subcutaneous fat area (cm2). RESULTS A total of 13 articles, published between 1997 and 2018, fulfilled the selection criteria. Three probiotics were included, of which Lactobacillus was the most commonly studied (10 studies), followed by Bifidobacterium (two studies) and Pediococcus (one study). Probiotics significantly reduced BMI (P = 0.013), total cholesterol (P = 0.011), and low-density lipoprotein (P = 0.006) while increased high-density lipoprotein (P = 0.028);high heterogeneities were observed. Only Lactobacillus could decrease triglyceride level (P = 0.005) with low heterogeneity. No included studies reported fibrosis score, liver functions, subcutaneous fat outcomes. CONCLUSION Single probiotics, especially Lactobacillus, have a potentially beneficial effect on improving obesity and dyslipidemia. Evidence on the fatty liver is limited.展开更多
An increasing number of studies have indicated that gut microbiota and its metabolites are crucial in the development of hyperlipidemia.Bifidobacterium longum(B.longum)CCFM1077 has been shown to have lipid-lowering ef...An increasing number of studies have indicated that gut microbiota and its metabolites are crucial in the development of hyperlipidemia.Bifidobacterium longum(B.longum)CCFM1077 has been shown to have lipid-lowering effects in animals.This study aimed to evaluate the potential of B.longum CCFM1077 in lowering the lipid levels in patients with hyperlipidemia and investigate the effect of this bacterium on serum lipid abnormalities,gut microbiota,and fecal metabolites in these patients.This study was a six-week,randomized,double-blind,and placebo-controlled pilot clinical trial.Subjects with hyperlipidemia(N=62)were randomly assigned to receive placebo(N=31)or B.longum CCFM1077(1×1010colony-forming units(CFUs)per day;N=31).Serum lipid levels including total cholesterol(TC),lowdensity lipoprotein cholesterol(LDL-C),total triglyceride(TG),and high-density lipoprotein cholesterol(HDL-C)were examined at the baseline and interventio nal endpoints.Changes in the gut microbiota composition and diversity were measured based on 16S ribosomal RNA(rRNA)sequencing of the V3-V4region at the end of the intervention period.Non-targeted metabolomics of the feces was performed using ultra-performance liquid chromatography(UPLC)-Q-Exactive Orbitrap/mass spectrometer.Oral administration of B.longum CCFM1077 for six weeks significantly decreased the serum levels of TC(p<0.01)and LDL-C(p<0.01)in patients with hyperlipidemia.B.longum CCFM1077 treatment markedly increased gut microbiota diversity and the relative abundance of anti-obesity-related genera,including Lactobacillus,Butyricicoccus,Bifidobacterium,and Blautia,whereas it decreased the relative abundance of obesity-related genera,including Alistipes,Megamonas,and Catenibacterium.Additionally,some key metabolites(bile acids(BAs),biotin,and caffeine)and their corresponding metabolic pathways(primary BA biosynthesis,and taurine and hypotaurine,biotin,purine,and caffeine metabolisms)were enriched by B.longum CCFM1077,and thus it may lower lipid levels.B.longum CCFM1077 is a probiotic strain with the potential to lower serum TC and LDL-C levels patients with hyperlipidemia.The underlying mechanism may be related to the increased abundance of anti-obesity-related genera and fecal metabolites.These findings provide a foundation for future clinical applications of lipid-lowering probiotics in managing individuals with hyperlipidemia.展开更多
采用溶钙圈法从传统发酵肉制品中分离乳酸菌菌株,通过清除胆固醇、甘油三酯能力及胆盐水解酶活性测定筛选潜在改善高脂血症乳酸菌菌株。基于此,结合体外益生特性研究,利用主成分分析(PCA)筛选综合益生活性较好的菌株,并通过形态观察、...采用溶钙圈法从传统发酵肉制品中分离乳酸菌菌株,通过清除胆固醇、甘油三酯能力及胆盐水解酶活性测定筛选潜在改善高脂血症乳酸菌菌株。基于此,结合体外益生特性研究,利用主成分分析(PCA)筛选综合益生活性较好的菌株,并通过形态观察、生理生化试验及分子生物学技术对其进行菌种鉴定,最后评价该菌株对HepG2细胞高脂模型中胆固醇和甘油三酯含量的影响。结果表明,从传统发酵肉制品中共分离得到125株乳酸菌,最终筛选得到1株具有潜在改善高脂血症能力且综合益生活性最好的菌株LC4,被鉴定为戊糖片球菌(Pediococcus pentosus),其体外胆固醇及甘油三酯清除率分别为74.73%和91.65%,具有胆盐水解酶活性;模拟胃液及肠液的耐受力分别为87.57%和72.70%,在0.3%胆盐条件下处理24 h活菌数为9.79 lg CFU/mL,在pH 2.5酸条件下处理4 h,活菌数为7.67 lg CFU/mL;24 h后的自聚集能力为52.77%;对二甲苯、乙酸乙酯及氯仿的疏水性分别为78.13%、34.07%和10.30%。HepG2细胞高脂模型经菌株LC4处理后,降低了胆固醇和甘油三酯含量。展开更多
目的探讨布拉酵母菌对大鼠高脂血症的防治作用。方法将40只SPF级SD大鼠随机分为4组,每组10只。A组饲喂普通饲料;B组饲喂高脂饲料;C组饲喂高脂饲料同时于第70天加用布拉酵母菌散剂;D组饲喂高脂饲料同时加布拉酵母菌散剂。实验第1天、第7...目的探讨布拉酵母菌对大鼠高脂血症的防治作用。方法将40只SPF级SD大鼠随机分为4组,每组10只。A组饲喂普通饲料;B组饲喂高脂饲料;C组饲喂高脂饲料同时于第70天加用布拉酵母菌散剂;D组饲喂高脂饲料同时加布拉酵母菌散剂。实验第1天、第70天、第112天采集4组大鼠血液检测大鼠血脂四项。结果第70天时,B组、C组大鼠血清总胆固醇(total cholesterol,TC)(mmol/L)(B组:2.39±0.21 vs 1.93±0.15,C组:2.45±0.29 vs 1.94±0.24)、三酰甘油(triacylglycerol,TG)(mmol/L)(B组:1.04±0.21 vs 0.74±0.13,C组:1.02±0.18 vs 0.76±0.15)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)(mmol/L)(B组:1.04±0.12 vs 0.46±0.12,C组:1.06±0.16 vs 0.46±0.07)较初始升高(P<0.05)。D组大鼠血清TC较初始无变化(2.05±0.14 vs 1.98±0.21,P>0.05),TG降低(0.53±0.12 vs 0.77±0.22,P<0.05),LDL-C虽有升高(0.74±0.15 vs 0.48±0.09)但较B组(0.74±0.15 vs 1.04±0.12)、C组(0.74±0.15 vs 1.06±0.16)低(P<0.05)。第112天时,C组大鼠血清TC(2.13±0.19 vs 2.45±0.29)、TG(0.46±0.07 vs 1.02±0.18)、LDL-C(0.56±0.16 vs 0.81±0.11)较第70天时降低(P<0.05),且低于B组(2.13±0.19 vs 2.60±0.18,0.46±0.07 vs 1.06±0.22,0.56±0.16 vs 0.72±0.09,P<0.01)。结论高脂饲料饲喂会造成大鼠血脂明显升高,布拉酵母菌可预防高脂血症的发生。展开更多
基金Supported by The Thailand Research Fund and Panacee Group Co.,Ltd,No.RDG6150124Ratchadapiseksompotch Fund(Matching fund),Faculty of Medicine,Chulalongkorn University,No.RA-MF-12/62
文摘BACKGROUND A number of non-systematic reviews on the effects or mechanisms of probiotics on improving dyslipidemia, fatty liver, and obesity have been available but inconclusive to determine the independent effects of probiotics on each of the three conditions. AIM To perform a systematic review and meta-analysis on potential benefits of probiotics among individuals with fatty liver or obesity or hyperlipidemia. METHODS A systematic literature search was performed using PubMed and Embase. Adult participants of any gender without major comorbidities who received probiotics were considered following these criteria:(1) Studies on a single genus of probiotics with or without prebiotics;(2) Studies specifying the probiotic dosage into colony-forming units (CFUs);and (3) Studies on food-based probiotics were excluded. The primary outcome measures for fatty liver, obesity, and dyslipidemia were fibrosis score (kPa), body mass index (BMI;kg/m2), and serum lipid profiles (mg/dL), respectively. The secondary outcome measures for fatty liver and obesity were liver enzymes (U/L) and subcutaneous fat area (cm2). RESULTS A total of 13 articles, published between 1997 and 2018, fulfilled the selection criteria. Three probiotics were included, of which Lactobacillus was the most commonly studied (10 studies), followed by Bifidobacterium (two studies) and Pediococcus (one study). Probiotics significantly reduced BMI (P = 0.013), total cholesterol (P = 0.011), and low-density lipoprotein (P = 0.006) while increased high-density lipoprotein (P = 0.028);high heterogeneities were observed. Only Lactobacillus could decrease triglyceride level (P = 0.005) with low heterogeneity. No included studies reported fibrosis score, liver functions, subcutaneous fat outcomes. CONCLUSION Single probiotics, especially Lactobacillus, have a potentially beneficial effect on improving obesity and dyslipidemia. Evidence on the fatty liver is limited.
基金supported by the Natural Science Foundation of Jiangsu Province(BK20220155 and BE2021623)the National Natural Science Foundation of China(32021005,U1903205,and 32001665)the Key Scientific and Technological Research Projects in the Key Areas of the Xinjiang Production and Construction Corps(2018AB010)。
文摘An increasing number of studies have indicated that gut microbiota and its metabolites are crucial in the development of hyperlipidemia.Bifidobacterium longum(B.longum)CCFM1077 has been shown to have lipid-lowering effects in animals.This study aimed to evaluate the potential of B.longum CCFM1077 in lowering the lipid levels in patients with hyperlipidemia and investigate the effect of this bacterium on serum lipid abnormalities,gut microbiota,and fecal metabolites in these patients.This study was a six-week,randomized,double-blind,and placebo-controlled pilot clinical trial.Subjects with hyperlipidemia(N=62)were randomly assigned to receive placebo(N=31)or B.longum CCFM1077(1×1010colony-forming units(CFUs)per day;N=31).Serum lipid levels including total cholesterol(TC),lowdensity lipoprotein cholesterol(LDL-C),total triglyceride(TG),and high-density lipoprotein cholesterol(HDL-C)were examined at the baseline and interventio nal endpoints.Changes in the gut microbiota composition and diversity were measured based on 16S ribosomal RNA(rRNA)sequencing of the V3-V4region at the end of the intervention period.Non-targeted metabolomics of the feces was performed using ultra-performance liquid chromatography(UPLC)-Q-Exactive Orbitrap/mass spectrometer.Oral administration of B.longum CCFM1077 for six weeks significantly decreased the serum levels of TC(p<0.01)and LDL-C(p<0.01)in patients with hyperlipidemia.B.longum CCFM1077 treatment markedly increased gut microbiota diversity and the relative abundance of anti-obesity-related genera,including Lactobacillus,Butyricicoccus,Bifidobacterium,and Blautia,whereas it decreased the relative abundance of obesity-related genera,including Alistipes,Megamonas,and Catenibacterium.Additionally,some key metabolites(bile acids(BAs),biotin,and caffeine)and their corresponding metabolic pathways(primary BA biosynthesis,and taurine and hypotaurine,biotin,purine,and caffeine metabolisms)were enriched by B.longum CCFM1077,and thus it may lower lipid levels.B.longum CCFM1077 is a probiotic strain with the potential to lower serum TC and LDL-C levels patients with hyperlipidemia.The underlying mechanism may be related to the increased abundance of anti-obesity-related genera and fecal metabolites.These findings provide a foundation for future clinical applications of lipid-lowering probiotics in managing individuals with hyperlipidemia.
文摘采用溶钙圈法从传统发酵肉制品中分离乳酸菌菌株,通过清除胆固醇、甘油三酯能力及胆盐水解酶活性测定筛选潜在改善高脂血症乳酸菌菌株。基于此,结合体外益生特性研究,利用主成分分析(PCA)筛选综合益生活性较好的菌株,并通过形态观察、生理生化试验及分子生物学技术对其进行菌种鉴定,最后评价该菌株对HepG2细胞高脂模型中胆固醇和甘油三酯含量的影响。结果表明,从传统发酵肉制品中共分离得到125株乳酸菌,最终筛选得到1株具有潜在改善高脂血症能力且综合益生活性最好的菌株LC4,被鉴定为戊糖片球菌(Pediococcus pentosus),其体外胆固醇及甘油三酯清除率分别为74.73%和91.65%,具有胆盐水解酶活性;模拟胃液及肠液的耐受力分别为87.57%和72.70%,在0.3%胆盐条件下处理24 h活菌数为9.79 lg CFU/mL,在pH 2.5酸条件下处理4 h,活菌数为7.67 lg CFU/mL;24 h后的自聚集能力为52.77%;对二甲苯、乙酸乙酯及氯仿的疏水性分别为78.13%、34.07%和10.30%。HepG2细胞高脂模型经菌株LC4处理后,降低了胆固醇和甘油三酯含量。
文摘目的探讨布拉酵母菌对大鼠高脂血症的防治作用。方法将40只SPF级SD大鼠随机分为4组,每组10只。A组饲喂普通饲料;B组饲喂高脂饲料;C组饲喂高脂饲料同时于第70天加用布拉酵母菌散剂;D组饲喂高脂饲料同时加布拉酵母菌散剂。实验第1天、第70天、第112天采集4组大鼠血液检测大鼠血脂四项。结果第70天时,B组、C组大鼠血清总胆固醇(total cholesterol,TC)(mmol/L)(B组:2.39±0.21 vs 1.93±0.15,C组:2.45±0.29 vs 1.94±0.24)、三酰甘油(triacylglycerol,TG)(mmol/L)(B组:1.04±0.21 vs 0.74±0.13,C组:1.02±0.18 vs 0.76±0.15)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)(mmol/L)(B组:1.04±0.12 vs 0.46±0.12,C组:1.06±0.16 vs 0.46±0.07)较初始升高(P<0.05)。D组大鼠血清TC较初始无变化(2.05±0.14 vs 1.98±0.21,P>0.05),TG降低(0.53±0.12 vs 0.77±0.22,P<0.05),LDL-C虽有升高(0.74±0.15 vs 0.48±0.09)但较B组(0.74±0.15 vs 1.04±0.12)、C组(0.74±0.15 vs 1.06±0.16)低(P<0.05)。第112天时,C组大鼠血清TC(2.13±0.19 vs 2.45±0.29)、TG(0.46±0.07 vs 1.02±0.18)、LDL-C(0.56±0.16 vs 0.81±0.11)较第70天时降低(P<0.05),且低于B组(2.13±0.19 vs 2.60±0.18,0.46±0.07 vs 1.06±0.22,0.56±0.16 vs 0.72±0.09,P<0.01)。结论高脂饲料饲喂会造成大鼠血脂明显升高,布拉酵母菌可预防高脂血症的发生。
